Back to top
more

Elanco Animal Health (ELAN)

(Delayed Data from NYSE)

$13.79 USD

13.79
5,034,462

+0.11 (0.80%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $13.80 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?

by Zacks Equity Research

DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.

Zacks Equity Research

ELAN vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELAN vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Medical Stocks Lagging Encompass Health (EHC) This Year?

by Zacks Equity Research

Here is how Encompass Health (EHC) and Elanco Animal Health Incorporated (ELAN) have performed compared to their sector so far this year.

Zacks Equity Research

Are Options Traders Betting on a Big Move in ELAN Stock?

by Zacks Equity Research

Investors need to pay close attention to Elanco Animal Health Incorporated (ELAN) stock based on the movements in the options market lately.

Zacks Equity Research

What Makes Elanco Animal Health (ELAN) a New Buy Stock

by Zacks Equity Research

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

ELAN vs. USPH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELAN vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Encompass Health (EHC) and Elanco Animal Health Incorporated (ELAN) have performed compared to their sector so far this year.

Zacks Equity Research

Is the Options Market Predicting a Spike in Elanco Animal Health Stock?

by Zacks Equity Research

Investors need to pay close attention to ELAN stock based on the movements in the options market lately.

Zacks Equity Research

Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 19.35% and 2.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Astrana Health, Inc. (ASTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Chemed (CHE) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 0.54% and 1.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elanco Animal Health (ELAN) Soars 12.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Elanco Animal Health (ELAN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Elanco Animal Health (ELAN) stock based on the movements in the options market lately.

Zacks Equity Research

Elanco Animal Health (ELAN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Q4 Earnings Miss Estimates

by Zacks Equity Research

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of -6.67% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exploring Analyst Estimates for Elanco Animal Health (ELAN) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Get a deeper insight into the potential performance of Elanco Animal Health (ELAN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Compared to Estimates, Elanco Animal Health (ELAN) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Q3 Earnings Top Estimates

by Zacks Equity Research

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 8.33% and 0.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elanco Animal Health (ELAN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Elanco Animal Health (ELAN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

by Kinjel Shah

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.

Zacks Equity Research

Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Kinjel Shah headshot

Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.